Cargando…

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice

Introduction Phase 3 trials have shown comparable efficacy of direct oral anticoagulants (DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE), with less major bleeding events in patients randomized to DOAC treatment. With DOACs being increasingly used in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendriks, Stephan V., Klok, Frederikus A., Stenger, Wilhelmina J.E., Mairuhu, Albert T.A., Eikenboom, Jeroen, Fogteloo, Jaap, Huisman, Menno V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314657/ https://www.ncbi.nlm.nih.gov/pubmed/32607465 http://dx.doi.org/10.1055/s-0040-1713683

Ejemplares similares

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study
por: Mahé, Isabelle, et al.
Publicado: (2021)

Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey
por: Kaptein, Fleur H.J., et al.
Publicado: (2023)

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

First do no harm
por: Huisman, Menno V., et al.
Publicado: (2022)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
por: Kooiman, Judith, et al.
Publicado: (2015)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations
por: Martens, Emily S. L., et al.
Publicado: (2022)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Comment from Huisman et al.
por: Huisman, Menno V., et al.
Publicado: (2022)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Prophylaxis and treatment of COVID-19 related venous thromboembolism
por: Kaptein, F.H.J., et al.
Publicado: (2021)

Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism
por: Ende-Verhaar, Yvonne M., et al.
Publicado: (2018)

Vaccine-induced immune thrombotic thrombocytopenia
por: Klok, Frederikus A, et al.
Publicado: (2022)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Chest X-Ray Not Routinely Indicated Prior to the YEARS Algorithm in the Diagnostic Management of Suspected Pulmonary Embolism
por: van der Pol, Liselotte M., et al.
Publicado: (2019)

Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations
por: Nab, Linda, et al.
Publicado: (2022)

Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2021)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer
por: Anijs, Rayna J. S., et al.
Publicado: (2022)

Health-related quality of life after first venous thromboembolism in individuals aged 70 years and older
por: Wang, Huijie, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis
por: Delluc, Aurélien, et al.
Publicado: (2020)

Pulmonary flow profile and distensibility following acute pulmonary embolism
por: Klok, Frederikus A, et al.
Publicado: (2011)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_viesvlm2iral2j9gr79k73mjm5